Tarsus Pharmaceuticals advertising spend, FY2025
Tarsus Pharmaceuticals (TARS) reported $121M of advertising expense for the fiscal year ended Dec 31, 2025. That is 26.9% of revenue of $451M. Up 306.7% from FY2024.
Key facts
- Ad spend is 13x its FY2023 level ($9.4M), slower than revenue (26x).
- FY2025 is the highest year on file, going back to FY2022.
- Ad spend has risen 2 years in a row.
- Tarsus Pharmaceuticals spends more on advertising than 33% of the 458 US-listed companies tracked. Its ad-to-revenue ratio is 5.9x the median of 4.5%.
Ad spend by fiscal year
Ad spend as % of revenue
Ad spend in context, FY2025
Advertising was 28.4% of selling, general and administrative expense. Advertising was 1.9x research and development spending. The company reported an operating loss of $71M.
| Advertising | $121M | AdvertisingExpense |
|---|---|---|
| Selling, general and administrative | $427M | ad spend = 28.4% |
| Research and development | $64.3M | ad spend = 1.9x R&D |
| Operating loss | -$71M | |
| Net loss | -$66.4M |
Same fiscal year and filing as the ad spend. Selling and marketing and SG&A usually include advertising.
History
Download CSV| Fiscal year | Period end | Ad spend | YoY | Revenue | Ad / revenue | Tag | Filing |
|---|---|---|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | $121M | +306.7% | $451M | 26.9% | AdvertisingExpense | 10-K Feb 23, 2026 |
| FY2024 | Dec 31, 2024 | $29.8M | +217.0% | $183M | 16.3% | AdvertisingExpense | 10-K Feb 23, 2026 |
| FY2023 | Dec 31, 2023 | $9.4M | n/a | $17.4M | 53.9% | AdvertisingExpense | 10-K Feb 23, 2026 |
| FY2022 | Dec 31, 2022 | $0 | n/a | $25.8M | 0.0% | AdvertisingExpense | 10-K Feb 25, 2025 |
Ad spend, revenue and the ratio come from the linked filing. YoY compares each year with the fiscal year directly before it, under the same tag. A gap, a change of tag or a change of fiscal year end leaves it blank. A $0 value is what the filing tagged for that year.
What the figure is
Advertising costs as disclosed in the annual report (XBRL tag AdvertisingExpense).
Compared with similar spenders
The 6 companies closest to Tarsus Pharmaceuticals in latest-year ad spend.
| Rank | Company | Ad spend | Ad / revenue | YoY | Fiscal year |
|---|---|---|---|---|---|
| 305 | Generac | $123M | 2.9% | +5.7% | FY2025 |
| 306 | Lyft | $123M | 1.9% | -10.2% | FY2025 |
| 307 | Snowflake | $122M | 2.6% | +16.3% | FY2026 |
| 308 | Insulet | $121M | 4.5% | +43.9% | FY2025 |
| 309 | Tarsus Pharmaceuticals | $121M | 26.9% | +306.7% | FY2025 |
| 310 | Ziff Davis | $119M | 8.2% | +4.0% | FY2025 |
| 311 | Cisco Systems | $119M | 0.2% | -36.0% | FY2026 |
Full ranking of 458 companies · Biggest increases #3 · Highest ad-to-revenue #25 · New $50M spenders #1 · More on ads than R&D #65 · Ads above operating profit #108
Questions
How much does Tarsus Pharmaceuticals spend on advertising?
Tarsus Pharmaceuticals spent $121M on advertising in fiscal 2025, the year ended Dec 31, 2025, according to its 10-K filed Feb 23, 2026.
What percentage of revenue does Tarsus Pharmaceuticals spend on advertising?
26.9% of revenue in fiscal 2025 ($121M against $451M). The median across the 458 companies tracked is 4.5%.
Is Tarsus Pharmaceuticals spending more on advertising?
Yes. Ad spend rose 306.7% in fiscal 2025 from fiscal 2024. It has risen 2 years in a row.
How does Tarsus Pharmaceuticals rank by advertising spend?
#309 of 458 US-listed companies with $50M or more in ad spend, ranked on each company's latest fiscal year.
Does Tarsus Pharmaceuticals spend more on advertising than on R&D?
Yes. In fiscal 2025 it spent $121M on advertising and $64.3M on research and development.
What does Tarsus Pharmaceuticals's advertising figure include?
Advertising costs as disclosed in the annual report (XBRL tag AdvertisingExpense).
Company and source
- Filing
- 10-K for FY2025, filed Feb 23, 2026
- Accession number
0001819790-26-000019- Company
- Tarsus Pharmaceuticals, Inc., CIK 1819790, SIC 2836 (Biological Products, (No Diagnostic Substances))
- Headquarters
- Irvine, CA
- Incorporated in
- DE
- Fiscal year ends
- December 31
- Listed on
- Nasdaq
- SEC filer status
- Large accelerated filer
- Data
- SEC EDGAR XBRL company facts, retrieved Nov 18, 2026. Methodology.
- Cite
- Tarsus Pharmaceuticals advertising spend, FY2022-FY2025. Aleksei Trudov, io.trudov.com, from SEC EDGAR XBRL company facts (latest: 10-K filed Feb 23, 2026), retrieved Nov 18, 2026. https://io.trudov.com/company/tarsus-pharmaceuticals/advertising-spend/
- Download
- CSV, all years · CSV, all 458 companies